文献速递衰弱、肌少症与跌倒老年慢病共病管理

血管紧张素系统抑制剂对老年人躯体功能影响的系统综述与荟萃分析

Effect of Angiotensin System Inhibitors on Physical Performance in Older People - A Systematic Review and Meta-Analysis.
PubMed 文献 · J Am Med Dir Assoc · 2020-08-26

该系统综述与荟萃分析纳入8项随机对照试验共952名老年人,评估ACEi或ARB对比安慰剂、常规照护或其他降压药对躯体功能的影响。结果显示,在耐力、力量及简易体能状况量表(SPPB)方面均无显著效应,现有证据不支持将ACEi或ARB作为单一干预改善老年人躯体功能。

要点

  • 纳入8项RCT共952人,ACEi 6项、ARB 2项,平均年龄66–79岁。
  • 耐力结局无显著效应:6项试验SMD 0.04(95%CI -0.22至0.29),P=.77。
  • 力量及SPPB结局亦无显著效应,证据不支持单一用药改善躯体功能。

核心结论

  • 现有证据不支持使用ACEi或ARB作为单一干预来改善老年人的躯体功能。

研究设计与样本

  • 系统综述与荟萃分析,纳入8项随机对照试验,共952名参与者。
  • 入选试验比较ACEi或ARB与安慰剂、常规照护或其他降压药,平均年龄≥65岁。
  • 检索多个电子数据库至2020年2月底,无语言限制。
  • 排除平均年龄<65岁或针对已知影响肌肉功能疾病(如心力衰竭)的试验。

主要发现

  • 耐力结局:6项试验,SMD 0.04(95%CI -0.22至0.29),P=.77,I²=53%。
  • 力量结局:6项试验,SMD -0.02(95%CI -0.18至0.14),P=.83,I²=21%。
  • 简易体能状况量表(SPPB):3项试验,SMD -0.04(95%CI -0.19至0.11),P=.60,I²=0%。
  • 漏斗图目视检查未发现发表偏倚证据。

关键数值与推荐

  • 纳入试验平均年龄范围66至79岁,治疗持续时间2个月至1年。
  • 试验招募健康老年人及功能受损者,无试验专门针对肌少症老年人。
  • 所有试验偏倚风险为低至中等。

临床怎么用

  • 不应将ACEi或ARB作为改善老年人躯体功能的单一干预措施。
  • 临床决策仍需以降压等明确适应证为主要依据。

局限性

  • 纳入试验数量较少(8项),总样本量952人。
  • 无试验专门针对肌少症老年人,结果外推至该人群需谨慎。
  • 治疗持续时间较短(2个月至1年),长期效应未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Preclinical and observational data suggest that angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) may be able to improve physical performance in older people via direct and indirect effects on skeletal muscle. We aimed to summarize current evidence from randomised controlled trials in this area. DESIGN: Systematic review and meta-analysis. SETTING AND PARTICIPANTS: Randomized controlled trials enrolling older people, comparing ACEi or ARB to placebo, usual care or another antihypertensive agent, with outcome data on measures of physical performance. METHODS: We searched multiple electronic databases without language restriction between inception and the end of February 2020. Trials were excluded if the mean age of participants was <65 years or treatment was targeting specific diseases known to affect muscle function (for example heart failure). Data were sought on measures of endurance and strength. Standardized mean difference (SMD) treatment effects were calculated using random-effects models with RevMan software. RESULTS: Eight trials (952 participants) were included. Six trials tested ACEi, 2 trials tested ARBs. The mean age of participants ranged from 66 to 79 years, and the duration of treatment ranged from 2 months to 1 year. Trials recruited healthy older people and people with functional impairment; no trials specifically targeted older people with sarcopenia. Risk of bias for all trials was low to moderate. No significant effect was seen on endurance outcomes [6 trials, SMD 0.04 (95% CI -0.22 to 0.29); P = .77; I2 = 53%], strength outcomes [6 trials, SMD -0.02 (95% CI -0.18 to 0.14), P = .83, I2 = 21%] or the short physical performance battery [3 trials, SMD -0.04 (95% CI -0.19 to 0.11), P = .60, I2 = 0%]. No evidence of publication bias was evident on inspection of funnel plots. CONCLUSIONS AND IMPLICATIONS: Existing evidence does not support the use of ACE inhibitors or angiotensin receptor blockers as a single intervention to improve physical performance in older people.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Caulfield L, Heslop P, Walesby KE, et al. Effect of Angiotensin System Inhibitors on Physical Performance in Older People - A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2020. PMID: 32859513. doi:10.1016/j.jamda.2020.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。